OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Philip Scheltens

1 Projects | 1 Researchers | $855,541 Invested

2021

Vrije Universiteit Amsterdam

Philip Scheltens

Testing low-dose efavirenz treatment for Alzheimer’s disease: a phase 1b dosing, target-engagement and exploratory biomarker study.

  • Funding Amount: $855,541
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Active